Contineum Therapeutics, Inc. 4

CEO Carmine N. Stengone exercised 2,500 stock options at $1.01 and sold 2,500 Contineum Therapeutics (CTNM) Class A shares at an average of $16.4566 on 2026-09-08 under a 10b5-1 plan.

On September 8, 2026, Carmine N. Stengone, CEO and President of Contineum Therapeutics, Inc., exercised 2,500 stock options at $1.01 per share and immediately sold the same 2,500 shares of Class A Common Stock at a weighted average price of $16.4566 per share under a Rule 10b5-1 trading plan, generating an estimated gross sale value of about $41,000 and an option exercise cost of about $2,500. Following these transactions, his direct ownership stood at 17,217 shares of Class A Common Stock, which, using the disclosed sale price as a proxy, is worth approximately $285,000, while 2,500 options with a $1.01 exercise price and a February 24, 2030 expiration were reduced by the exercised amount. The sale is characterized as a routine, pre-planned option exercise-and-sell transaction under the company’s equity incentive plan, rather than an open-market discretionary purchase or sale, and the filing notes that the sale price was a weighted average over trades executed between $16.29 and $16.59 per share.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

4

Source Type

fda

Accession

0001628280-26-060962

Alert Tier

5